The FDA approved the first generic version of rifapentine tablets, previously marketed as Priftin. Rifapentine is indicated for active pulmonary tuberculosis in patients aged 12 years and older and ...

The U.S. Food and Drug Administration (FDA) on June 11 issued an Emergency Use Authorization (EUA) for generic nitenpyram tablets for the treatment of New World screwworm (NWS) infestations (myiasis) ...

Hikma Pharmaceuticals didn’t run afoul of patent law in marketing a copycat version of Amarin’s heart drug Vascepa, the Supreme Court ruled Thursday, in a decision that could help protect makers of ...

WASHINGTON, June 4 (Reuters) - Drugmaker Hikma's (HIK.L), opens new tab generic version of Amarin Pharma's (AMRN.O), opens new tab cardiovascular medication Vascepa did not infringe Amarin's patents, ...

Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter ...

WASHINGTON, June 4 (Reuters) - Drugmaker Hikma's generic version of Amarin Pharma's cardiovascular medication Vascepa did not infringe Amarin's patents, the U.S. Supreme Court ruled on Thursday in a ...

Amarin Pharma has not done enough to definitively show that its generic competitor, Hikma Pharmaceuticals, is infringing on Amarin's patents for its anti-hypertriglyceridemia drug icosapent ethyl ...

(The Center Square) - The U.S. Supreme Court, in a unanimous decision on Thursday, ruled that a cardiovascular drugmaker did not violate America's patent laws. The ruling could allow for generic drug ...

Hims & Hers announced it will offer generic semaglutide through its direct-to-consumer virtual care platform to eligible customers in Canada, following Novo Nordisk's loss of Canadian patent ...

LinkedIn is cracking down on AI-generated “slop” by suppressing generic posts from recommendations rather than removing them. The platform claims 94 per cent detection accuracy in early tests, but has ...

Americans are unlikely to see generic versions of semaglutide — the active ingredient in Novo Nordisk’s Ozempic and Wegovy — until at least the end of 2031, according to a May 13 NBC News report. Novo ...